Research programme: cancer therapy - Bayer/Pharmagene
Latest Information Update: 22 Mar 2010
At a glance
- Originator Bayer; Pharmagene
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 May 2005 Suspended - Preclinical for Cancer in United Kingdom (unspecified route)
- 26 May 2005 Suspended - Preclinical for Cancer in USA (unspecified route)
- 03 Apr 2003 No development reported - Preclinical for Cancer in United Kingdom (unspecified route)